ALK and adenocarcinoma: An ALK rearrangement is detected in 3 to 7% of patients with stage IIIB/IV NSCLC, depending on the series and also probably according to the selection of the patients for molecular testing; in most cases it concerns an adenocarcinoma [11,12,13,14,15].